Actively Recruiting
Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma
Led by Regina Elena Cancer Institute · Updated on 2025-06-12
20
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.
CONDITIONS
Official Title
Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients over 18 years of age
- Histological diagnosis of clear cell renal cell carcinoma
- Evidence of advanced or metastatic disease
- Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI)
- Patients able to comply with the study procedures
- Patients who give written informed consent personally or through a witness before starting any study procedure
You will not qualify if you...
- Previous neoplasms
- Previous antineoplastic treatments
- Previous steroid treatments
- Active viral infections such as HCV or HIV
- Lack of autonomy in adhering to study procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
"Regina Elena" National Cancer Institute
Rome, Italy, 00144
Actively Recruiting
Research Team
F
Fabio Calabrò, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here